IQ EQ FUND MANAGEMENT IRELAND Ltd Has $1.43 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 166.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,264 shares of the company’s stock after acquiring an additional 22,647 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in CRISPR Therapeutics were worth $1,427,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of CRSP. The Manufacturers Life Insurance Company raised its stake in CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after purchasing an additional 231 shares in the last quarter. Intellectus Partners LLC raised its position in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after buying an additional 250 shares in the last quarter. Farrow Financial Inc. lifted its holdings in shares of CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after acquiring an additional 270 shares during the period. Sunbelt Securities Inc. increased its stake in CRISPR Therapeutics by 11.3% in the third quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock valued at $139,000 after acquiring an additional 300 shares during the last quarter. Finally, Kestra Private Wealth Services LLC raised its position in CRISPR Therapeutics by 1.5% during the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after purchasing an additional 310 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CRSP has been the topic of several recent analyst reports. Chardan Capital decreased their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Barclays lifted their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada dropped their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, March 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $73.11.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $38.04 on Friday. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $70.12. The business’s 50-day moving average is $43.17 and its 200-day moving average is $45.23. The company has a market capitalization of $3.26 billion, a price-to-earnings ratio of -8.70 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Greene bought 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now directly owns 7,000 shares in the company, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.